The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).
The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC). Therefore, in the absence of a BAP1 and DICER1 abnormality, we offer to sequence your whole genome (WGS) or partial genome (genotyping) for a previously unknown genetic abnormality. Furthermore, the discovery of new genes would be a major medical advance that could contribute to the identification of new therapeutic targets. This research will be conducted at the University Hospital of Nantes and the Hospital of Vendée and 95 people should participate.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
34
Whole Genome sequencing
Vendée Hospital
La Roche-sur-Yon, France
Nantes University Hospital
Nantes, France
Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer
To be achieved by a whole genome sequencing (WGS) approach in a familial analysis of patients with differentiated thyroid cancer. In addition, high-throughput genotyping of multiple individuals in each family will allow complementary detection of genomic regions that are shared only by affected subjects
Time frame: within 2 years
Number of phenotypes associated to genotypes of CDT
By studying the association between the clinical characteristics of patients and the identified genetic variants
Time frame: within 2 years
Analysis of birthplace/family origin information
Definition of the spatial location of family forms of CDT and to identify possible founding effects
Time frame: within 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.